Pharmacokinetics of lamotrigine in children in the absence of other antiepileptic drugs

被引:35
作者
Chen, C
Casale, EJ
Duncan, B
Calverhouse, EH
Gilman, J
机构
[1] Glaxo Wellcome Inc, Div Clin Pharmacol, Res Triangle Pk, NC 27709 USA
[2] Glaxo Wellcome Inc, Div Cent Nervous Syst Clin Res, Res Triangle Pk, NC 27709 USA
[3] Glaxo Wellcome Inc, Div Clin Pharmacol Data Sci, Res Triangle Pk, NC 27709 USA
[4] Glaxo Wellcome Inc, Div Bioanal & Drug Metab, Res Triangle Pk, NC 27709 USA
[5] Miami Childrens Hosp, Dept Neurosci, Miami, FL USA
来源
PHARMACOTHERAPY | 1999年 / 19卷 / 04期
关键词
D O I
10.1592/phco.19.6.437.31052
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
We evaluated the pharmacokinetics of lamotrigine in 12 children with epilepsy who were receiving no other antiepileptic drugs. Each patient received a single oral dose of lamotrigine 2 mg/kg. Plasma concentrations of the drug were measured up to 48 hours after dosing. Pharmacokinetic parameters were calculated using concompartmental methods. After rapid absorption, the lamotrigine concentration declined monoexponentially. Oral clearance was 0.64 +/- 0.26 ml/min/kg. The apparent volume of distribution was 1.50 +/- 0.51 L/kg. Weight-normalized clearance and volume were higher in children than in adults. The mean half-life was 32 hours, similar to that in adults. Should similar plasma lamotrigine: concentrations in adults and children be desirable, children will likely require higher weight-normalized doses at the same dosing frequency.
引用
收藏
页码:437 / 441
页数:5
相关论文
共 33 条
  • [11] THE PREVALENCE AND INCIDENCE OF CONVULSIVE DISORDERS IN CHILDREN
    HAUSER, WA
    [J]. EPILEPSIA, 1994, 35 : S1 - S6
  • [12] Population pharmacokinetics of lamotrigine monotherapy in patients with epilepsy: Retrospective analysis of routine monitoring data
    Hussein, Z
    Posner, J
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 43 (05) : 457 - 465
  • [13] CONTROLLED TRIAL OF LAMOTRIGINE (LAMICTAL) FOR REFRACTORY PARTIAL SEIZURES
    JAWAD, S
    RICHENS, A
    GOODWIN, G
    YUEN, WC
    [J]. EPILEPSIA, 1989, 30 (03) : 356 - 363
  • [14] PHARMACOLOGICAL STUDIES ON LAMOTRIGINE, A NOVEL POTENTIAL ANTIEPILEPTIC DRUG .2. NEUROCHEMICAL STUDIES ON THE MECHANISM OF ACTION
    LEACH, MJ
    MARDEN, CM
    MILLER, AA
    [J]. EPILEPSIA, 1986, 27 (05) : 490 - 497
  • [15] LEVITON A, 1982, Neuroepidemiology, V1, P40, DOI 10.1159/000110688
  • [16] A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED CROSSOVER ADD-ON TRIAL OF LAMOTRIGINE IN PATIENTS WITH TREATMENT-RESISTANT PARTIAL SEIZURES
    LOISEAU, P
    YUEN, AWC
    DUCHE, B
    MENAGER, T
    ARNEBES, MC
    [J]. EPILEPSY RESEARCH, 1990, 7 (02) : 136 - 145
  • [17] PLACEBO-CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF LAMOTRIGINE IN PATIENTS WITH PARTIAL SEIZURES
    MATSUO, F
    BERGEN, D
    FAUGHT, E
    MESSENHEIMER, JA
    DREN, AT
    RUDD, GD
    LINEBERRY, CG
    MADSEN, JA
    RISTANOVIC, R
    ERENBERG, G
    KRAMER, RE
    HARNER, RN
    SCHOMER, DL
    LEPPIK, I
    COLLINS, SD
    KING, KW
    SHAMSNIA, M
    WHITE, RL
    GAY, PE
    ROTHNER, AD
    DRAKE, ME
    DETOLEDO, J
    SUSSMAN, NM
    MIKATI, MA
    OLSON, D
    FROMM, G
    MURRO, AM
    EHLE, A
    FOLEY, JF
    MORRIS, HH
    SMITH, DB
    SO, EL
    SCHACHTER, SC
    KUZNIECKY, R
    LAXER, K
    GALLAGHER, BB
    WEISBERG, LA
    MOORE, EL
    [J]. NEUROLOGY, 1993, 43 (11) : 2284 - 2291
  • [18] LAMOTRIGINE THERAPY FOR PARTIAL SEIZURES - A MULTICENTER, PLACEBO-CONTROLLED, DOUBLE-BLIND, CROSS-OVER TRIAL
    MESSENHEIMER, J
    RAMSAY, RE
    WILLMORE, LJ
    LEROY, RF
    ZIELINSKI, JJ
    MATTSON, R
    PELLOCK, JM
    VALAKAS, AM
    WOMBLE, G
    RISNER, M
    [J]. EPILEPSIA, 1994, 35 (01) : 113 - 121
  • [19] Mullens Lynette, 1996, Epilepsia, V37, P163
  • [20] DRUG-METABOLISM IN PREGNANCY, INFANCY AND CHILDHOOD
    PERUCCA, E
    [J]. PHARMACOLOGY & THERAPEUTICS, 1987, 34 (01) : 129 - 143